Adult ALL Treatment at Diagnosis

GIMEMA Guidelines for the Treatment of Adult ALL Affected Patients at Diagnosis

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00537550

Acronym

LAL2000

Enrollment

Unknown

Registered

2007-10-01

Start date

2000-07-31

Completion date

2006-06-30

Last updated

2007-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leukemia, Lymphocytic, Acute

Keywords

ALL, Adult

Brief summary

The present study has been designed to give participating centers the possibility of better understanding the diagnostic and prognostic factors of ALL patients.

Interventions

DRUGVincristine

Steroids pre-treatment

DRUGVincristin, Daunorubicine, Asparaginase, Methotrexate

Induction therapy

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

14 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Diagnosis of acute lymphoblastic leukemia (ALL) * Negative myeloperoxidase stain * Phenotype T (ALL-T) and B(ALL-B)

Exclusion criteria

* Creatinine \> 2.5mg/dL after adequate hydratation * LVEF \<50% * Presence of documented infections not responding to antibiotic and/or antifungal therapy * Presence of concomitant malignant diseases * Absence of any psychological condition that does not allow to intake high doses of cortisone * Patients who have received any antineoplastic chemiotherapy for more than 5 days * Patients who have received any steroids for more than 10 days

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026